STOCKS TELEGRAPH

Tag: NRXP

  • NRx Pharmaceuticals Inc. (NRXP) Bullish After Hours on its Upcoming COVID-19 Vaccine Presentation

    On January 07, NRx Pharmaceuticals Inc. (NRXP) announced its upcoming company updates presentation at the H.C. Wainwright BioConnect conference. The company will be discussing new details of its Covid-19 vaccine trial during the presentation. Consequently, the stock became bullish in the after-hours on the news.

    During regular trading, NRXP stock lost 7.34% at its closing price of $4.67 on Friday. Following the announcement, the stock gained 6.85% at $4.99 in the after-hours session.

    The clinical-stage small molecule pharmaceutical company, NRx Pharmaceuticals Inc. has a market capitalization of $274.64 million. Currently, the company has 58.81 million shares outstanding in the market.

    NRXP Recent Developments

    As per Friday’s latest announcement, the company will be presenting at the H.C. Wainwright BioConnect Virtual Conference, on January 10, 2022. The Chairman of NXRP’s Board and CEO, Prof. Jonathan Javitt, MD, MPH will be discussing the company’s business updates. Further, he will also provide new details on the company’s late-stage trials of BriLifeTM Covid-19 vaccine.

    NRXP is developing BriLifeTM vaccines against Covid-19. It is being developed under exclusive license from the Israel Ministry of Defense by the Institute for Biological Research. As new strains of the SARS-CoV-2 virus are emerging, the company is expanding its trials to include the new variants. Furthermore, the preliminary data showed the effectiveness of its BriLife vaccines against the Delta variant, last month. Moreover, the company has also advanced to now include reviewing data on BriLife vaccine’s effectiveness against the Omicron Variant.

    Hence, the company plans on presenting the preliminary data along with new developments in the vaccine’s clinical trials in the upcoming conference.

    In addition, the company also announced a change in the timings of the presentation. Previously, it was to be at 7 am EST on Monday, which has now been updated to 9 am EST on Monday.

    Q3 Financial Updates

    On November 16, the company announced its financial results for the third quarter of 2021, which ended on September 30, 2021.

    NRXP incurred a net loss of $20.8 million in the third quarter of 2021, against $5.2 million in Q3 of 2020. Resultantly, the net loss per basic and diluted share in the third quarter of 2021, was $0.40, against $0.15 in the year-ago period.

    Moreover, in the Q3 of 2021, the Research and Development expenses, and the General and Administrative expenses were $6.3 million and $13.8 million, respectively. This compares to respective $4.3 million and $3.8 million in Q3 of 2020.

  • NRx Pharmaceuticals, Inc. (NRXP) Stock Surges ZYESAMI Role in Pandemic Response

    NRx Pharmaceuticals, Inc. (NRXP) Stock Surges ZYESAMI Role in Pandemic Response

    NRx Pharmaceuticals, Inc. (NRXP) stock prices skyrocketed by 42.84% shortly after market trading commenced on July 19th 2021, bringing the price per share up to USD$12.17 early on in the trading day.

    ZYESAMI’s Role in Covid-19

    July 21st, 2021 saw the company announce data about ZYESAMI (aviptadil) at the Disease Control and Prevention Summit., in regard to the role of the treatment in preventing Cytokine Storm in Covid-19 patients. The presentation will showcase the statistically significant effect of ZYESAMI in mitigating the sharp rise in cytokines, which are closely linked to mortality in Covid-19 patients. This was consolidated by the completion of a recent Phase 2b/3 trial of ZYESAMI, wherein the change in cytokine level was a prespecified endpoint.

    Details of the Study

    Patients treated in the study showed a minimal increase in IL-6, as compared to patients treated with a placebo reported a statistically significant elevation in interleukin 6 cytokine levels. The patient set was diverse, with varying levels of the severity of Covid-19 infection and distribution among both tertiary care and community hospitals.

    Accelerated Development

    The findings have been submitted to the U.S. Food and Drug Administration as supplements to the Emergency Use Authorization application that has been submitted as is currently pending. The company is also submitting a biomarker letter of intent to the FDA as a part of its biomarker program, as pre the authorization of the 21st Century Cures Act.

    Scope of ZYESAMI

    With Covid-19 hospitalizations continuing to rise around the world, the placebo-controlled biomarker data signals the critical role that ZYESAMI has the potential to play in the prevention of the sudden elevation of cytokines that is linked to mortality. A biomarker-based regulatory path seems cleared on the basis of the link established between the clinical effect of ZYESAMI on survival and recovery in conjunction with measurable biologic chance in cytokine levels. The effects of a cytokine storm are lethal and are associated with mortality resulting from a variety of fatal conditions, including, but not limited to, Acute Respiratory Distress Syndrome, a common cause of death in sepsis, and amniotic fluid embolus.

    Future Outlook for NRXP

    Armed with a highly promising advancement in the fight against the continuing global coronavirus pandemic, NRXP is poised to capitalize on the prospective market space that has become accessible to it. With such spearheaded market penetration, current and potential investors are hopeful that management will be able to leverage their resources to facilitate effective distribution of the offering in a timely manner to ensure maximum profitability.